KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers
JCO Precision Oncology · 2024
DOI: 10.1200/po.24.00263 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Rebecca Gelfer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins p21(ras), Biliary Tract Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
PURPOSE KRAS variants are associated with poor outcomes in biliary tract cancers (BTCs). This study assesses the prevalence of KRAS variants and their association with survival and recurrence in patients with intrahepatic cholangiocarcinoma (IHC), extrahepatic cholangiocarcinoma (EHC), and gallbladder adenocarcinoma (GB). METHODS In this cross-sectional, single-institution study at Memorial Sloan Kettering, tumors from 985 patients treated between 2004 and 2022 with IHC, EHC, and GB who underwent either curative-intent resection or were treated with chemotherapy for unresectable disease were used for targeted sequencing. RESULTS Of the 985 patients sequenced, 15% had a KRAS mutation. Five hundred and seventy-two had unresectable disease (n = 395 IHC, n = 71 EHC, n = 106 GB) and 413 were treated with curative-intent resection (n = 175 IHC, n = 119 EHC, and n = 119 GB). Median follow-up time was 18 months (IQR, 11-31). KRAS G12D mutations were most common in IHC (38%) and EHC (37%) tumors. Mutations in SF3B1 co-occurred with mutant KRAS in IHC and EHC, with comutant resectable patients having worse survival after adjusting for tumor type (hazard ratio [HR], 4.04 [95% CI, 1.45 to 11.2]; P = .007). KRAS G12 mutations were associated with worse survival in patients with IHC compared with wild-type (WT) or other KRAS mutations, regardless of resection status (unresectable P < .001, resectable P = .011). After adjusting for clinical covariates, KRAS G12 mutations remained a prognostic indicator for patients with IHC compared with WT (HR, 1.99 [95% CI, 1.41 to 2.80]; P < .001). CONCLUSION The adverse impact of KRAS mutations in BTC is driven by G12 alterations in patients with IHC regardless of resection status, which was not observed in GB or EHC. There are unique comutational partners in distinct BTC subsets. These differences have important clinical implications in the era of KRAS-targeted therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Surgery, Vilnius University Hospital, Vilnius, Lithuania.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Department of Medicine, Weill Cornell Medicine, New York, NY.
- Trinity School of Medicine, Trinity College Dublin, Dublin, Ireland.
ORCID-Profile: Rebecca Gelfer, Yi Song, James Harding, Ghassan K Abou-Alfa, Eileen M O'Reilly, Wungki Park, Rohit Chandwani, Alice Wei, Kevin Soares, Mithat Gonen, William R Jarnagin
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIBIB NIH HHS
Zitieren
APA
Gelfer, R., Gulla, A., Kalvin, H. L., Song, Y., Harding, J., Abou-Alfa, G. K., O'Reilly, E. M., Park, W., Chandwani, R., Wei, A., Kingham, P., Drebin, J., Balachandran, V., D'Angelica, M., Soares, K., Gonen, M., & Jarnagin, W. R. (2024). KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers. JCO Precision Oncology. https://doi.org/10.1200/po.24.00263
Vancouver
Gelfer R, Gulla A, Kalvin HL, Song Y, Harding J, Abou-Alfa GK, et al. KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers. JCO Precision Oncology. 2024. doi:10.1200/po.24.00263
BibTeX
@article{Gelfer2024,
author = {Gelfer, Rebecca and Gulla, Aiste and Kalvin, Hannah L and Song, Yi and Harding, James and Abou-Alfa, Ghassan K and O'Reilly, Eileen M and Park, Wungki and Chandwani, Rohit and Wei, Alice and Kingham, Peter and Drebin, Jeffrey and Balachandran, Vinod and D'Angelica, Michael and Soares, Kevin and Gonen, Mithat and Jarnagin, William R},
title = {KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers},
journal = {JCO Precision Oncology},
year = {2024},
doi = {10.1200/po.24.00263}
}
EUVIMED